
    
      A phase 2b, open label study to assess the hemodynamic effects of increasing doses of pulsed,
      inhaled nitric oxide (iNO) in subjects with pulmonary hypertension associated with pulmonary
      fibrosis or sarcoidosis on long term oxygen therapy followed by an open label extension study
    
  